Company news

CNS Pharmaceuticals, Inc. news in 2025

CNS Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

CNS Pharmaceuticals Announces CEO Transition

December 17, 2025

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 17, 2025

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

November 10, 2025

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 15, 2025

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

August 14, 2025

CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

July 22, 2025

CNS Pharmaceuticals Announces Reverse Stock Split

July 18, 2025

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

July 9, 2025

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287

June 25, 2025

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

June 24, 2025

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

June 5, 2025

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 16, 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

May 13, 2025

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

April 1, 2025

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

March 25, 2025

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

February 26, 2025

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

February 20, 2025

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

February 19, 2025

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

February 18, 2025

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

February 9, 2025

Decks in 2025